Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
While the FDA has approved cannabis-derived prescription drug, Epidiolex, for three rare seizure disorders, not much has changed for people with other forms of epilepsy. Joseph Sirven, a Fla.-based neurologist who specializes in epilepsy, said all his patients now ask about it. Despite the buzz, he and other physicians said they’re reluctant to advise patients on over-the-counter CBD because they don’t know what’s in the bottles. A study in Epilepsy & Behavior on 11 oils found three contained less CBD than claimed, and four held more, with one containing 28% more CBD than advertised. Meanwhile, problems persist with Epidiolex, as users struggle with their insurance companies given the list price of $32,500 per year. The Washington Post
U.S. District Judge Susan D. Wigenton again refused to hear claims brought by men who said they tested positive for THC after consuming a hemp tea that promised 0.0% of the psychoactive ingredient. Ricardo Santiago and Vaughn Frederick attempted to revive three claims in their second amended complaint against Total Life Changes, which sold the tea. As with the previous filing, the judge said the pleadings were too vague to support the consumers’ claims. Furthermore, she rejected claims made under the state’s deceptive trade practices law, saying they lacked specificity. Law 360 (sub. req.)
The bill allows any products over 0.5 mg of THC per dose to be deemed...
"Breaking news: Sri Lanka has been removed from the United Nations," says superimposed Sinhala-language text on a Facebook graphic shared on September 25, 2026 The graphic also features a photo of...